Algeta

Algeta Receives IND Approval for Alpharadin(TM) to Commence Clinical Development in the USA

... OSLO, February 21 /PRNewswire-FirstCall/ -- algeta ASA (OSE: ALGETA), the cancer therapeutics company...ent of Alpharadin(TM) in HRPC patients in the USA. algeta filed its Investigational New Drug (IND) applicati...ted. Following the start up of the BC1-08 trial, algeta will continue discussions with the FDA to agree on...

Algeta in Medical Technology

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

...one Metastases in Major Cancer Indications algeta ASA (OSE: ALGETA), the cancer therapeutics company...is in preparation, which if successful will enable algeta to market Alpharadin, either alone or in combinati...the phase II program is an important milestone for algeta that gives us great confidence in the potential of...

Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin

...s With Hormone Refractory Prostate Cancer (HRPC) algeta ASA (OSE: ALGETA), the Norwegian cancer therapeuti... world to our unique approach to treating HRPC." algeta has recently started enrolling patients for the pi...Royal Marsden Hospital in the UK. About Algeta algeta ASA is a Norwegian cancer therapeutics company bui...

Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO

... OSLO, Norway, 30 May 2007 - algeta ASA (OSE: ALGETA), the Norwegian cancer therapeuti...w@citigatedr.co.uk Citigate Dewe Rogerson About algeta algeta ASA (algeta ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... 5. Drug Approvals and Clinical Studies II-53 Debiopharm Unveils Results of Phase III Study of Trelstar in Prostate Cancer Treatment II-53 algeta to Start Clinical Study of Alpharadin in HRPC II-53 Ferring Receives FDA Approval for Degarelix in Prostate Cancer II-53 Isis and OncoGenex Re...

Algeta Appoints Andrew Kay as President and Chief Executive Officer

... of Alpharadin in Advanced Prostate Cancer algeta ASA (OSE: ALGETA), the Norwegian cancer therapeuti... (CTO). Mr. Kay (53), B. Pharm., will join algeta from Renovo plc (LSE: RNVO) where he was Executive...in the company and will be of significant value to algeta in bringing Alpharadin to market." Mr. Kay...